Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 206

Sort by

Sort Order Select

Journal Articles

Suboptimal/Reduced Therapy in Older Patients with T-Cell Lymphoma Resulted in Poorer Outcomes: Report from the International T-Cell Project 1.0

Tetiana Skrypets, Onder Alpdogan, Luana Conte, Monica Civallero, Athina Lymboussaki, Julie M. Vose, Ivan Dlouhy, Maria Elena Cabrera, Felicitas Hitz, Sabela Bobillo, Won Seog Kim, Arnon Nagler, Dario Marino, Ranjana H. Advani, Caterina Stelitano, Pierluigi Porcu, Massimo Federico

Blood (2024) 144 (Supplement 1): 6402.

https://doi.org/10.1182/blood-2024-203976

Published: 2024

Journal Articles

Long Term Follow up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma

Sandra Frimpong, Valerie K Shostrom, Robert Gregory Bociek, Matthew Lunning, Christopher D' Angelo, James Olen Armitage, Julie M. Vose

Blood (2024) 144 (Supplement 1): 6327.

https://doi.org/10.1182/blood-2024-201621

Published: 2024

Journal Articles

Analysis of Surveillance Imaging and Outcomes for Relapsed CNS Lymphoma Using Novel Agents

Matthew Gromowsky, Shristi Upadhyay Banskota, Smriti Sharma, Robin High, Robert Gregory Bociek, Matthew Lunning, Julie M. Vose, Christopher D'Angelo

Blood (2024) 144 (Supplement 1): 7777.

https://doi.org/10.1182/blood-2024-206305

Published: 2024

Journal Articles

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

Swaminathan P Iyer, LaQuisa Hill, Steven Horwitz, Salvia Jain, Christina Poh, Julie M. Vose, Malcolm K. Brenner, Maksim Mamonkin, Sarah Hein, Federica Giordano, Alice Bexon

Blood (2024) 144 (Supplement 1): 7223.

https://doi.org/10.1182/blood-2024-201523

Published: 2024

Journal Articles

Trial in Progress: Open-Label Phase 1 Study to Evaluate Safety of SGN-35C in Adults with Select Relapsed/Refractory Lymphomas (SGN35C-001)

Alex F. Herrera, Swetha Kambhampati, Michael A Spinner, Christina Poh, Elizabeth H. Phillips, Vincent Ribrag, Ming Jin Yan, Tara Chen, Julie M. Vose

Blood (2024) 144 (Supplement 1): 1674.1.

https://doi.org/10.1182/blood-2024-194011

Published: 2024

Journal Articles

An Llmpp Study: Genomic Characterization of Novel PTCL- Biological Subtypes Reveal Distinctive Therapeutic Vulnerabilities

Blood (2024) 144 (Supplement 1): 456.

https://doi.org/10.1182/blood-2024-209396

Published: 2024

Journal Articles

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4480.

https://doi.org/10.1182/blood-2024-198714

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Blood (2024) 144 (Supplement 1): 887.

https://doi.org/10.1182/blood-2024-200339

Published: 2024

Journal Articles

A Prospective Clinical Trial of Boom-Boom Radiation As Bridging Therapy for Patients with Large B-Cell Lymphoma Undergoing Treatment with Lisocabtagene Maraleucel (Liso-cel) Therapy

Christopher R D'Angelo, Charles Enke, Julie M. Vose, Robert Gregory Bociek, Fang Yu, Makayla Schissel, Matthew Lunning

Blood (2024) 144 (Supplement 1): 3126.

https://doi.org/10.1182/blood-2024-208472

Published: 2024

Journal Articles

Impact of Icans on Long-Term Neurocognitive Function in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy

Olivia Leighton Makos, Valerie K Shostrom, James Olen Armitage, Julie M. Vose, Matthew Lunning, Robert Gregory Bociek, Christopher R D'Angelo

Blood (2024) 144 (Supplement 1): 2368.

https://doi.org/10.1182/blood-2024-194010

Published: 2024

Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2023-180048

Published: 2023

Journal Articles

Increased Exceptional Response and Overall Survival Advantage for Patients with Multiple Myeloma Receiving Melphalan 200mg/m 2 Vs 140 Mg/m 2 Conditioning for Autologous Hematopoietic Stem Cell Transplantation

Sarah Tjards, Robin High, Matthew A Lunning, Tanya M. Wildes, Julie M. Vose, Muhamed Baljevic, Sarah A. Holstein, Christopher R D'Angelo

Blood (2023) 142 (Supplement 1): 4966.

https://doi.org/10.1182/blood-2023-179971

Published: 2023

Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 3026.

https://doi.org/10.1182/blood-2023-181309

Published: 2023

Journal Articles

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Blood (2023) 142 (Supplement 1): 1729.

https://doi.org/10.1182/blood-2023-180333

Published: 2023

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 981.

https://doi.org/10.1182/blood-2023-181627

Published: 2023

Journal Articles

Patients with Private Insurance Endure Significantly Longer Delays in Time from Intent to CAR-T to Apheresis (Brain-2-Vein) in Multiple Treated Diffuse Large B-Cell Lymphoma: Analysis By Cellular Therapy Intent Quotient (CTIQ)

Matthew Gromowsky, Valerie Shostrom, Kimberly Schmidt-pokorny, James Olen Armitage, Julie M. Vose, Robert Gregory Bociek, Christopher D'Angelo, Matthew A Lunning

Blood (2023) 142 (Supplement 1): 258.

https://doi.org/10.1182/blood-2023-181344

Published: 2023

Journal Articles

Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 2993.

https://doi.org/10.1182/blood-2023-186530

Published: 2023

Journal Articles

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Blood (2023) 142 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2023-179868

Published: 2023

Journal Articles

Genomic profiling for clinical decision making in lymphoid neoplasms

Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M. Horwitz, Ari M. Melnick, William G. Morice, Ryan D. Morin, Bertrand Nadel, Stefano A. Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P. Treon, Andrew D. Zelenetz, Ranjana H. Advani, Carl E. Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy B. Cook, Francesco d’Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L. Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L. King, Young H. Ko, Ann S. LaCasce, Georg Lenz, José I. Martin-Subero, Miguel A. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J. Rodig, Andreas Rosenwald, Gilles A. Salles, Jesus San-Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier L. Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott

Blood (2022) 140 (21): 2193–2227.

https://doi.org/10.1182/blood.2022015854

Published: 2022

Includes: Supplemental data

Journal Articles

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Blood (2022) 140 (Supplement 1): 3839–3841.

https://doi.org/10.1182/blood-2022-157105

Published: 2022

NARROW

Suboptimal/Reduced Therapy in Older Patients with T-Cell Lymphoma Resulted in Poorer Outcomes: Report from the International T-Cell Project 1.0

Long Term Follow up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma

Analysis of Surveillance Imaging and Outcomes for Relapsed CNS Lymphoma Using Novel Agents

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

Trial in Progress: Open-Label Phase 1 Study to Evaluate Safety of SGN-35C in Adults with Select Relapsed/Refractory Lymphomas (SGN35C-001)

An Llmpp Study: Genomic Characterization of Novel PTCL- Biological Subtypes Reveal Distinctive Therapeutic Vulnerabilities

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

A Prospective Clinical Trial of Boom-Boom Radiation As Bridging Therapy for Patients with Large B-Cell Lymphoma Undergoing Treatment with Lisocabtagene Maraleucel (Liso-cel) Therapy

Impact of Icans on Long-Term Neurocognitive Function in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Increased Exceptional Response and Overall Survival Advantage for Patients with Multiple Myeloma Receiving Melphalan 200mg/m 2 Vs 140 Mg/m 2 Conditioning for Autologous Hematopoietic Stem Cell Transplantation

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Patients with Private Insurance Endure Significantly Longer Delays in Time from Intent to CAR-T to Apheresis (Brain-2-Vein) in Multiple Treated Diffuse Large B-Cell Lymphoma: Analysis By Cellular Therapy Intent Quotient (CTIQ)

Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Genomic profiling for clinical decision making in lymphoid neoplasms

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only